Author

Mark A. Hull 1

1 University of Leeds,Leeds Institute of Biomedical and Clinical Sciences,Leeds,United Kingdom

COX-2 MEDIATES RESISTANCE TO EICOSAPENTAENOIC ACID IN COLORECTAL CANCER CELLS. 

Milene Volpato, Louise Coletta, Mark A. Hull

EICOSAPENTAENOIC ACID (EPA) AND/OR ASPIRIN FOR PREVENTION OF COLORECTAL ADENOMAS (THE SEAFOOD POLYP PREVENTION TRIAL): A MULTICENTRE DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED 2X2 FACTORIAL PHASE 3 TRIAL

Mark A. Hull, Kirsty Sprange, Trish Hepburn, Wei Tan, Aisha Shafayat, Colin J. Rees, Gayle Clifford, Richard Logan, Paul M. Loadman, Liz Williams, Diane Whitham, Alan Montgomery, Group seAFOod Trial Collaborative

EICOSAPENTAENOIC ACID-FREE FATTY ACID PREVENTS AND SUPPRESSES COLONIC TUMOURS IN COLITIS-ASSOCIATED COLORECTAL CANCER.

Giulia Piazzi, Anna Prossomariti, Giuseppe D'Argenio, Vincenzo Lembo, Giovanna Mazzone, Paola Vitaglione, Vincenzo Fogliano, Alessandra Munarini, Claudio Ceccarelli, chiara fazio, Leonarda D'Angelo, Andrea Belluzzi, Pasquale Chieco, Marco Romano, Franco Bazzoli, Luigi Ricciardiello, Mark A. Hull

HIGH DEFINITION WHITE LIGHT ENDOSCOPY (HDWLE) VERSUS HIGH DEFINITION WITH CHROMOENDOSCOPY (HDCE) IN THE DETECTION OF DYSPLASIA IN LONG STANDING ULCERATIVE COLITIS: A RANDOMIZED CONTROLLED TRIAL.

Noor Mohammed, Prashant Kant, Faisal Abid, Olorunda Rotimi, Padmini Prasad, P Hamlin, Simon M. Everett, Bjorn Rembacken, Mark A. Hull, Venkataraman Subramanian

HIGH PREVALENCE OF LIVER DISEASE AND OBESITY AMONGST A COLONOSCOPY POPULATION

Sara Koo, Linda Sharp, Stuart McPherson, Mark A. Hull, Steven P Rushton, Laura Neilson, Colin J. Rees

Inflammatory bowel disease associated colorectal cancer: Characteristics and outcomes from an English population dataset (2010 to 2016)

Nicholas E Burr, Rebecca Birch, John Taylor, Amy Downing, Paul Finan, Mark A. Hull, Venkataraman Subramanian, Roland Valori, Matt Rutter, Eva Morris

INTESTINAL LUMEN OMEGA-3 POLYUNSATURATED FATTY ACID LEVELS AFTER ORAL SUPPLEMENTATION

Gael R. Nana, Henry Watson, Milene Volpato, Amanda D Race, Paul M. Loadman, Giles J. Toogood, Mark A. Hull

OPIATE USE IN INFLAMMATORY BOWEL DISEASE. PRESCRIPTION TRENDS AND MORTALITY IN AN ENGLISH PRIMARY CARE COHORT FROM 1990-2014.

Nicholas E Burr, Chris Smith, Robert West, Mark A. Hull, Venkataraman Subramanian

POST-COLONOSCOPY COLORECTAL CANCER RATES IN IBD ARE HIGH AND VARY BY NHS TRUST IN ENGLAND

Nicholas E Burr, Roland Valori, Venkataraman Subramanian, Mark A. Hull, Andy Smith, Eva Morris, Matt Rutter

PRELIMINARY RESULTS OF THE OBESITY RELATED COLORECTAL ADENOMA RISK (OSCAR) STUDY

Sara Koo, Linda Sharp, Mark A. Hull, Steven P Rushton, Laura Jane Neilson, Stuart McPherson, Colin J. Rees

Item 1 - 10 / 20
1
2